Investor Group Reduces Stake in Athira Pharma Below 5% Threshold
Athira Pharma, Inc.
Subscribe to track LONA
Premium users can add ticker alerts and receive realtime notification updates.
Filing Summary
Investor Group Reduces Stake in Athira Pharma Below 5% Threshold
Company: Athira Pharma, Inc. (CIK: 0001620463) Form: SCHEDULE 13G/A | Filed: 2025-10-10 Significance: Low
Filer: Oliveira Steven Michael Relationship: Passive Investor Group
Ownership Update: • Type: Change in Beneficial Ownership • Shares Owned After: 161,218 • Ownership Stake: 4.088% of Common Stock
Key Insight: A passive investor group led by Steven Oliveira has filed to report their ownership stake in Athira Pharma has fallen below the 5% reporting threshold. This indicates a reduction of their position.
Market Context: This type of filing is a standard regulatory requirement for investors who are no longer beneficial owners of more than 5% of a company's stock. It typically has a low market impact as it reflects a change in a passive investment portfolio.
This is PUBLIC SEC data for educational purposes. Not investment advice.
Comprehensive Analysis
SEC Filing Analysis: Athira Pharma, Inc. (CIK: 0001620463)
Executive Summary
- Trading Significance: Low
- Key Takeaway: A passive investor group, led by Steven Michael Oliveira, has reduced its stake in Athira Pharma, Inc., causing its beneficial ownership to fall below the 5% threshold. This is reported via a Schedule 13G/A, indicating the cessation of a significant passive investment position.
- Market Impact: The market impact is expected to be neutral to minimal. The exit of a passive investor is not typically viewed as a strong signal about the company's fundamentals, as the sale could be for various portfolio management reasons.
Company Information
| Field | Value |
|---|---|
| Company | Athira Pharma, Inc. |
| Ticker Symbol | Not provided in filing |
| CIK | 0001620463 |
| Industry | BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] |
Filer Information
| Field | Value |
|---|---|
| Name | Oliveira Steven Michael (and related entities) |
| CIK | 0001358629 |
| Title/Position | Not Applicable |
| Relationship | Passive Investor Group |
Filing Details
This filing is a Schedule 13G/A, which is an amendment to a previous filing, used by passive investors to report changes in ownership. It is not a transactional form like a Form 4.
| Field | Value |
|---|---|
| Form Type | SCHEDULE 13G/A |
| Event Date | 2025-10-01 |
| Security Type | Common Stock |
| Shares Owned After | 161,218 (by the group) |
| Percent of Class | 4.088% |
| Ownership Type | Indirect (Shared Dispositive Power) |
Market Impact Analysis
Stock Impact Prediction
- Direction: Neutral
- Reasoning: This filing indicates that a passive investor has reduced their holdings. While a large seller can create downward pressure, the information is now public and may already be priced in. Since the investor is passive (not an insider with privileged information), the signal is weak.
Volume & Sentiment
- Expected Volume Impact: Low. The transactions that led to this ownership change have already occurred.
- Sentiment Indicator: Neutral. This is a procedural filing and does not inherently suggest a bullish or bearish outlook on the company's future from an insider's perspective.
Investment Insights
Positive Market Indicators
- There are no direct positive indicators from this filing.
Risk Factors
- The exit of a significant shareholder could be perceived negatively, suggesting a lack of confidence, but the reasons are unknown.
- It signals that a source of past demand for the stock is now potentially a source of supply or has exited entirely.
Key Takeaways
- Passive Stake Reduction: The filing's primary purpose is to declare that the reporting group no longer holds a stake of 5% or more.
- No Insider Signal: As a 13G filer, the group certified it did not acquire the shares to influence or control the company. Therefore, this change should not be interpreted as a strategic move based on inside information.
- Informational, Not Actionable: This event is more of a historical record of a change in the shareholder base rather than a forward-looking catalyst.
Contextual Analysis
Timing Significance
The filing was triggered by an event on October 1, 2025, which is the date the group's ownership likely fell below the 5% mark. The filing was made promptly on October 10, 2025, in accordance with SEC rules.
Transaction Context
The filing does not detail specific sale transactions (e.g., prices or dates). It only reports the resulting ownership level. The change is a decrease from a previously held position that was above 5%.
Company Context
Analysis of this filing should be paired with recent news, financial performance, and clinical trial updates for Athira Pharma to understand the broader context in which this investor decided to reduce their stake.
Risk Assessment
Risk Level: Low
Risk Factors
- The filing itself presents minimal risk to the market. It is a backward-looking statement of fact.
Market Considerations
- Investors should monitor if other large holders follow suit, which could indicate a broader shift in institutional sentiment.
- The reduction in a large, concentrated holding could increase the stock's public float, potentially affecting liquidity.
IMPORTANT DISCLAIMER: This analysis is for informational purposes only and is not intended as investment advice. The information presented is based on publicly available SEC filings and should not be construed as a recommendation to buy, sell, or hold any securities. Past performance does not guarantee future results. All investments carry risk, including the potential loss of principal. Please consult with a qualified financial advisor before making any investment decisions.
Analysis generated on 2025-10-10 | Data source: SEC EDGAR
Get Real-Time Alerts
Join our community to receive instant notifications when high-significance filings are published
Important Disclaimer
This content is drawn from public SEC filings and may contain errors. It is for informational purposes only and is not investment, legal, or tax advice.
Nothing here is a recommendation to buy, sell, or hold any security. Do your own due diligence.